Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Charged multivesicular body protein 4B (CHMP4B) is a core component of the ESCRT-III complex, which plays a critical role in sorting endocytosed surface receptors into multivesicular endosomes for degradation, as well as in the scission of membrane necks during cytokinesis and the budding of enveloped viruses such as HIV-1. CHMP4B assembles into membrane-attached spiral or filamentous scaffolds that drive or stabilize membrane deformation and budding processes. Interaction with proteins such as ALIX (PDCD6IP) is essential for its function in the ESCRT pathway. Mutations in CHMP4B disrupt vesicular trafficking and are associated with autosomal dominant cataracts. Although this protein is biologically important, it is not currently the target of clinically approved drugs, but it has relevance in research on cell division, viral replication, and hereditary disease.
Not applicable: no drugs directly targeting CHMP4B are approved. For research compounds: hypothesized disruption of ESCRT-III polymerization or inhibition of protein-protein interactions needed for vesicle scission and viral budding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Charged multivesicular body protein 4B (CHMP4B).